HC Wainwright & Co. Reiterates Buy on Dare Bioscience, Maintains $7 Price Target
Portfolio Pulse from richadhand@benzinga.com
HC Wainwright & Co. analyst Douglas Tsao has reiterated a 'Buy' rating on Dare Bioscience (NASDAQ:DARE) and maintained a $7 price target.
August 11, 2023 | 12:27 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
HC Wainwright & Co. has reiterated a 'Buy' rating on Dare Bioscience and maintained a $7 price target.
The reiteration of a 'Buy' rating and maintenance of a $7 price target by HC Wainwright & Co. indicates a positive outlook for Dare Bioscience. This could potentially lead to an increase in investor confidence and a positive impact on the stock's price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100